Context Matters: Response Heterogeneity to Collagen-Targeting Approaches in Desmoplastic Cancers

Ashley M Fuller1, Tzipora S Karin Eisinger-Mathason1

  • 1Abramson Family Cancer Research Institute, Department of Pathology and Laboratory Medicine, Penn Sarcoma Program, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

Cancers
|July 9, 2022
PubMed

Insights

Tumor microenvironment research reveals collagen diversity. Understanding the 28 distinct collagen types and their varied roles is key to improving cancer therapies targeting the extracellular matrix.

Area of Science:

  • Oncology
  • Biochemistry
  • Extracellular Matrix Biology

Background:

  • Desmoplastic tissue deposition is a hallmark of the tumor microenvironment (TME).
  • Targeting the extracellular matrix (ECM) or collagen in tumors has yielded inconsistent results.
  • The heterogeneity of collagen molecules is a likely reason for these variable outcomes.

Purpose of the Study:

  • To review the diversity of the collagen family in normal tissues.
  • To highlight the context-specific roles of individual collagen molecules in desmoplastic tumors.
  • To explain the variable efficacy of collagen-targeting strategies due to collagen heterogeneity.

Main Methods:

  • Literature review of collagen structure, function, and distribution.
  • Analysis of individual collagen roles in the desmoplastic TME.
  • Synthesis of findings to guide future research in cancer therapy.

Main Results:

  • Mammalian tissues contain 28 distinct collagen types with unique structures and functions.
  • Individual collagen species can exhibit both pro- and anti-neoplastic effects within the TME.
  • Collagen heterogeneity explains the mixed efficacy of current therapeutic strategies.

Conclusions:

  • Recognizing the diversity of the collagen superfamily is critical for understanding tumor biology.
  • Future therapeutic strategies must account for specific collagen types and their roles in cancer.
  • Further research is needed to develop targeted therapies based on collagen heterogeneity.